SYRSSyros Pharmaceuticals Inc.
SYRS
Syros Pharmaceuticals Inc.2,863
Mkt Cap
$13,400.00Volume
5,797.0052W High
$3.4052W Low
$0.0001PE Ratio
0.00SYRS Fundamentals
Price
$0.0005Prev Close
$0.0008Open
$0.000550D MA
$0.0017Beta
11.02Avg. Volume
45,553.39P/B
-0.00Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans.
read more...
Benzinga·1y ago
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the...
Business Wire·1y ago
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial...
Business Wire·1y ago
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will...
Business Wire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·1y ago
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. (Syros or the Company) (NASDAQ: SYRS). Investors who...
Business Wire·1y ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·1y ago
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Syros Pharmaceuticals, Inc. (SYRS) Investigation...
PR Newswire·1y ago
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. (Syros or the Company) (NASDAQ: SYRS). Investors who...
Business Wire·1y ago